Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

Phase 3

Active, not recruiting

Conditions: Urothelial Cancer

Interventions: Drug: Gemcitabine
Biological: Nivolumab
Biological: Ipilimumab
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2017-01-30

Last Posted Date: 2024-10-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1322

Registration Number: NCT03036098

Locations: 🇺🇸
Local Institution - 0001, Anchorage, Alaska, United States
🇺🇸
Local Institution - 0115, Fresno, California, United States
🇺🇸
St Joseph Heritage Healthcare, Santa Rosa, California, United States

and more 171 locations

A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Biological: MASCT-I
Drug: Ifosfamide
Drug: PD1 antibody
Drug: Adriamycin
Drug: Gemcitabine
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2017-01-27

Last Posted Date: 2022-12-30

Lead Sponsor: HRYZ Biotech Co.

Target Recruit Count: 193

Registration Number: NCT03034304

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

and more 6 locations

WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer

Phase 1

Completed

Conditions: Hypopharynx Squamous Cell Carcinoma
Oral Cavity Squamous Cell Carcinoma
Larynx Cancer

Interventions: Drug: AZD1775
Drug: Cisplatin
Radiation: Radiotherapy

First Posted Date: 2017-01-23

Last Posted Date: 2022-11-14

Lead Sponsor: University of Birmingham

Target Recruit Count: 9

Registration Number: NCT03028766

Locations: 🇬🇧
St. James' University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom
🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧
The Royal Marsden Hospital, London, United Kingdom

and more 3 locations

A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

Phase 1

Completed

Conditions: Solid Tumor
Cholangiocarcinoma
Gall Bladder Carcinoma
Advanced Cancer
Metastatic Cancer
Biliary Tract Carcinoma
Non-Hodgkin's Lymphoma

Interventions: Drug: Merestinib
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2017-01-23

Last Posted Date: 2020-05-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 19

Registration Number: NCT03027284

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tokyo, Japan

Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis

Phase 3

Conditions: Stomach Neoplasm

Interventions: Procedure: Cytoreductive surgery
Procedure: Hyperthermic Intraperitoneal Chemotherapy
Drug: Fluoropyrimidine
Drug: Cisplatin

First Posted Date: 2017-01-18

Last Posted Date: 2019-09-13

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 220

Registration Number: NCT03023436

Locations: 🇨🇳
Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

and more 10 locations

Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 2

Conditions: Children
Nasopharyngeal Carcinoma

Interventions: Drug: Paclitaxel liposome
Drug: Cisplatin
Drug: 5-fu
Radiation: Radical radiotherapy

First Posted Date: 2017-01-13

Last Posted Date: 2019-08-07

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 37

Registration Number: NCT03020329

Locations: 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China

Paediatric Hepatic International Tumour Trial

Phase 3

Active, not recruiting

Conditions: Carcinoma, Hepatocellular
Hepatoblastoma

Interventions: Drug: Cisplatin
Drug: Doxorubicin
Drug: Carboplatin
Drug: Gemcitabine
Drug: 5Fluorouracil
Drug: Oxaliplatin
Drug: Vincristine
Drug: Etoposide
Drug: Sorafenib
Drug: Irinotecan

First Posted Date: 2017-01-11

Last Posted Date: 2024-05-13

Lead Sponsor: University of Birmingham

Target Recruit Count: 450

Registration Number: NCT03017326

Locations: 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Woluwe-Saint-Lambert, Belgium
🇮🇪
Children's Health Ireland Crumlin, Dublin, Ireland
🇮🇱
Schneider Children's Medical Center, Petach Tikva, Israel

and more 28 locations

Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma

Phase 3

Recruiting

Conditions: Locally Advanced Nasopharyngeal Carcinoma

Interventions: Drug: Docetaxel
Drug: Cisplatin
Radiation: IMRT/TOMO
Drug: Chemotherapy

First Posted Date: 2017-01-10

Last Posted Date: 2017-01-10

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 440

Registration Number: NCT03015727

Locations: 🇨🇳
Xiaozhong Chen, Hangzhou, Zhejiang, China

CISPLATIN + AZD-1775 In Breast Cancer

Phase 2

Completed

Conditions: Triple-negative Metastatic Breast Cancer

Interventions: Drug: Cisplatin
Drug: AZD1775

First Posted Date: 2017-01-06

Last Posted Date: 2021-11-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 34

Registration Number: NCT03012477

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

2015-12: a Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Thalidomide
Drug: Dexamethasone
Drug: Daratumumab
Drug: Cisplatin
Drug: Adriamycin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Melphalan
Procedure: ASCT
Drug: Lenalidomide
Drug: Bortezomib

First Posted Date: 2016-12-28

Last Posted Date: 2024-10-09

Lead Sponsor: University of Arkansas

Target Recruit Count: 50

Registration Number: NCT03004287

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy